Rafarma JSC is a full cycle pharmaceutical enterprise designed and operating in accordance with GMP standards. Rafarma is a part of the manufacturing segment of the PROTEK Group of Companies, engaged in R&D, manufacturing, distribution and retails.

    The full cycle manufacture of cephalosporin antibiotics, non-beta lactam antibiotics, cytostatic agents and formulations of other therapeutic classes is carried out at 5 self-contained sites.

    Its multi-purpose research and development facilities (25,000 sq m) are located in Terbuny, Lipetsk Region, Russia. Fitted with equipment from leading European suppliers, Rafarma JSC is capable of producing a wide range of ready formulations in 15 dosage forms.

    Rafarma’s multi-purpose research and development facilities are designed to focus on antibacterial and oncology products. They make up the bulk of the company’s portfolio, which also includes oral hypoglycemic, cardiovascular, antituberculosis and other preparations.

    The company also maintains facilities for manufacturing small-scale batches of APIs and solid forms based at the RAS Institute of Problems of Chemical Physics in Chernogolovka in the Moscow Region.

    Rafarma is a part of the manufacturing segment of the PROTEK Group of Companies, engaged in R&D, manufacturing, distribution and retails. The core element of the Group’s manufacturing segment is Sotex Pharmaceutical Company – an acknowledged national market leader and one of the few Russian companies holding EU GMP Certificate.

    • 25,000 sq m of manufacturing facilities in Terbuny, Lipetsk Region, Russia
    • 5 self-contained sites for the full cycle manufacture of cephalosporin antibiotics, non-beta lactam antibiotics, cytostatic agents and formulations of other therapeutic classes
    • R&D: research, development and testing laboratory, in-house experimental base at cleanroom
    • Manufacture of preparations in 15 dosage forms
    • Equipment supplied by the world’s leading manufacturers: Bosch, GLATT, Kilian, Romaco Macofar, IMA, CAM, Fedegari, and Tofflon among others.
    • 24 hectares are available for construction of additional manufacturing facilities
    • Availability of production facilities for contract manufacturing and area for additional construction
    • Local production and technology transfer experience
    • Attractive price-offer
    • Integrated business approach: production, distribution and promotion of medicines
    • Guaranteed sales volumes
    • Minimized ROI risks

    Site No 1 – R&D: research, development and testing laboratory, in-house experimental base
    Manufacturing of solid forms:
    pills, hard gelatin capsules, sachets,
    tubes

    Site No 2 – cephalosporins
    injections in vials, suspension vials

    Site No 3 – antineoplastics
    injections in vials, tablets and capsules

    Site No 4 – antibiotics
    non-β-lactam injections in vials tablets
    and capsules

    Site No 5 – antineoplastics
    injections in vials

    Annual Manufacturing Capacity:

    • 180 million hard gelatin capsules
    • 1.5 billion pills
    • 62.5 million injection vials
    • 7.5 million suspension vials
    • 18 million sachets

    Sotex PharmFirm - high-tech EU GMP certified manufacturer

    Sotex is the core element of the PROTEK Group of Companies’ manufacturing segment. Sotex is a major domestic pharmaceutical manufacturer, one of Russia’s most high-tech and innovative pharmaceutical enterprises.

    Production site located in Moscow Region provides a full manufacturing cycle of injection solutions in ampoules and syringes.

    In 2016, Sotex received European GMP certificate for ampoule production.

    Bayer, Sanofi, Novartis, Pierre Fabre, Takeda are among Sotex’ long-standing partners in the field of contract manufacturing.

    Facts & Figures

    • Rated 4th by IMS Health among Russian pharmaceutical manufacturers in 2016 in terms of output
    • Portfolio includes 148 SKUs with 97 branded products (30.06.2017)
    • Key therapeutic areas: oncology, neurology, rheumatology, nephrology, neuropsychiatry
    • Manufacturing capacity: 140 million ampoules and 6 million prefilled syringes annually
    • Unique line for manufacturing prefilled syringes with passive needle safety devices
    • Annual audits from world leading pharmaceutical manufacturers
    • R&D platform with competences of injectable and biotechnological product development
    • Exports to more than 10 countries

    Company news

    Get in touch with a specialist from the company!

    Get all the necessary information about the contract manufacture!